EP3107546A4 - Méthodes thérapeutiques faisant intervenir de la noribogaïne et des composés apparentés - Google Patents

Méthodes thérapeutiques faisant intervenir de la noribogaïne et des composés apparentés Download PDF

Info

Publication number
EP3107546A4
EP3107546A4 EP15751574.3A EP15751574A EP3107546A4 EP 3107546 A4 EP3107546 A4 EP 3107546A4 EP 15751574 A EP15751574 A EP 15751574A EP 3107546 A4 EP3107546 A4 EP 3107546A4
Authority
EP
European Patent Office
Prior art keywords
noribogaine
related compounds
therapeutic methods
methods employing
employing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP15751574.3A
Other languages
German (de)
English (en)
Other versions
EP3107546A2 (fr
Inventor
Lawrence Friedhoff
Emeline Maillet
Holger Weis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DemeRx Inc
Original Assignee
DemeRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/019692 external-priority patent/WO2015126434A1/fr
Priority claimed from US14/195,822 external-priority patent/US9345711B2/en
Priority claimed from US14/485,514 external-priority patent/US20150231147A1/en
Application filed by DemeRx Inc filed Critical DemeRx Inc
Publication of EP3107546A2 publication Critical patent/EP3107546A2/fr
Publication of EP3107546A4 publication Critical patent/EP3107546A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
EP15751574.3A 2014-02-18 2015-02-17 Méthodes thérapeutiques faisant intervenir de la noribogaïne et des composés apparentés Pending EP3107546A4 (fr)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US201461941390P 2014-02-18 2014-02-18
US201461941387P 2014-02-18 2014-02-18
US201461945746P 2014-02-27 2014-02-27
PCT/US2014/019692 WO2015126434A1 (fr) 2014-02-18 2014-02-28 Méthodes de traitement aigu et à long terme de la toxicomanie
US14/195,822 US9345711B2 (en) 2014-02-18 2014-03-03 Methods for acute and long-term treatment of drug addiction
US201461952727P 2014-03-13 2014-03-13
US201461952741P 2014-03-13 2014-03-13
US201461952731P 2014-03-13 2014-03-13
US201461952738P 2014-03-13 2014-03-13
US201461952733P 2014-03-13 2014-03-13
US201461952744P 2014-03-13 2014-03-13
US201462005847P 2014-05-30 2014-05-30
US201462005841P 2014-05-30 2014-05-30
US201462005858P 2014-05-30 2014-05-30
US201462005855P 2014-05-30 2014-05-30
US201462005851P 2014-05-30 2014-05-30
US14/292,632 US20150231146A1 (en) 2014-02-18 2014-05-30 Methods for acute and long-term treatment of drug addiction
US201462007346P 2014-06-03 2014-06-03
US201462024388P 2014-07-14 2014-07-14
US201462033538P 2014-08-05 2014-08-05
US201462035335P 2014-08-08 2014-08-08
US14/485,514 US20150231147A1 (en) 2014-02-18 2014-09-12 Methods for acute and long-term treatment of drug addiction
PCT/US2015/016186 WO2015126836A2 (fr) 2014-02-18 2015-02-17 Méthodes thérapeutiques faisant intervenir de la noribogaïne et des composés apparentés

Publications (2)

Publication Number Publication Date
EP3107546A2 EP3107546A2 (fr) 2016-12-28
EP3107546A4 true EP3107546A4 (fr) 2017-10-25

Family

ID=53879225

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15751574.3A Pending EP3107546A4 (fr) 2014-02-18 2015-02-17 Méthodes thérapeutiques faisant intervenir de la noribogaïne et des composés apparentés

Country Status (10)

Country Link
EP (1) EP3107546A4 (fr)
JP (1) JP2017506244A (fr)
KR (1) KR20160124829A (fr)
CN (1) CN106413718A (fr)
AU (2) AU2015219172A1 (fr)
CA (2) CA3221251A1 (fr)
EA (1) EA201691656A2 (fr)
IL (1) IL247325A0 (fr)
TW (1) TW201534306A (fr)
WO (1) WO2015126836A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014143201A1 (fr) 2013-03-15 2014-09-18 Demerx, Inc. Procédé pour le traitement avec la noribogaïne de l'addiction de patients sous méthadone
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
EP4279134A1 (fr) 2014-11-26 2023-11-22 DemeRx, Inc. Procédés et compositions pour potentialiser l'action d'analgésiques opioïdes en utilisant des alcaloïdes de l'iboga

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003127A1 (fr) * 1994-07-25 1996-02-08 Nda International, Inc. Procede et composition de traitement de la dependance chimique chez les mammiferes
WO1999011250A2 (fr) * 1997-09-04 1999-03-11 Novoneuron, Inc. Noribogaine utilisee pour le traitement de la douleur et de la toxicomanie
US7220737B1 (en) * 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
WO2014144508A2 (fr) * 2013-03-15 2014-09-18 Demerx, Inc. Procédé pour le traitement non toxique pour le sevrage médicamenteux

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153552A1 (en) * 2002-02-14 2003-08-14 Mash Deborah C. Method of treating chemical dependency in mammals and a composition therefor
MX2013000733A (es) * 2010-07-23 2013-05-30 Demerx Inc Composiciones de noribogaina.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003127A1 (fr) * 1994-07-25 1996-02-08 Nda International, Inc. Procede et composition de traitement de la dependance chimique chez les mammiferes
WO1999011250A2 (fr) * 1997-09-04 1999-03-11 Novoneuron, Inc. Noribogaine utilisee pour le traitement de la douleur et de la toxicomanie
US7220737B1 (en) * 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
WO2014144508A2 (fr) * 2013-03-15 2014-09-18 Demerx, Inc. Procédé pour le traitement non toxique pour le sevrage médicamenteux

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HEMENDRA N BHARGAVA ET AL: "Effects of noribogaine on the development of tolerance to antinociceptive action of morphine in mice", BRAIN RESEARCH, vol. 771, no. 2, 1 October 1997 (1997-10-01), AMSTERDAM, NL, pages 343 - 346, XP055406445, ISSN: 0006-8993, DOI: 10.1016/S0006-8993(97)00914-1 *
KOENIG XAVER ET AL: "Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug's cardiac ion channel profile", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 273, no. 2, 22 May 2013 (2013-05-22), pages 259 - 268, XP028784922, ISSN: 0041-008X, DOI: 10.1016/J.TAAP.2013.05.012 *
MICHAEL BAUMANN: "In vivo neurobiological effects of ibogaine and its O-desmethyl methabolite, 12-hydroxyibogamine (noribogaine) in rats)", 1 January 2001 (2001-01-01), XP055405640, Retrieved from the Internet <URL:http://jpet.aspetjournals.org/content/jpet/297/2/531.full.pdf> [retrieved on 20170912] *
STALLVIK MARIANNE ET AL: "Corrected QT interval during treatment with methadone and buprenorphine-Relation to doses and serum concentrations", DRUG AND ALCOHOL DEPENDENCE, ELSEVIER SCIENTIFIC PUBLISHERS, IR, vol. 129, no. 1, 16 October 2012 (2012-10-16), pages 88 - 93, XP028988598, ISSN: 0376-8716, DOI: 10.1016/J.DRUGALCDEP.2012.09.016 *

Also Published As

Publication number Publication date
IL247325A0 (en) 2016-09-29
WO2015126836A2 (fr) 2015-08-27
CN106413718A (zh) 2017-02-15
JP2017506244A (ja) 2017-03-02
CA2977636A1 (fr) 2015-08-27
AU2020267217B2 (en) 2022-04-07
AU2015219172A1 (en) 2016-09-29
CA2977636C (fr) 2024-01-02
KR20160124829A (ko) 2016-10-28
EA201691656A2 (ru) 2017-03-31
AU2020267217A1 (en) 2020-12-03
CA3221251A1 (fr) 2015-08-27
EP3107546A2 (fr) 2016-12-28
TW201534306A (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
EP3359168A4 (fr) Composés thérapeutiques et procédés
HK1243073A1 (zh) 治療性化合物及其用途
EP3199628A4 (fr) Agent thérapeutique induisant une cytotoxicité
EP3380101A4 (fr) Composés inhibiteurs d&#39;eif4-a et procédés associés
EP3154594A4 (fr) Agents thérapeutiques activés par fap, et utilisations associées
EP3102200A4 (fr) Composés et compositions thérapeutiques
EP3218005A4 (fr) Composés interagissant avec le glycane et procédés d&#39;utilisation
EP3229809A4 (fr) Composés et procédés impliquant des stérols
EP3020430A4 (fr) Canule pour thérapie d&#39;intégration de catgut
EP3097880A4 (fr) Appareil thérapeutique
EP3126634A4 (fr) Stimulation de puits
EP3231793A4 (fr) Composés de dihydropyrimidine-2-one et leurs utilisations médicales
EP3111932A4 (fr) Cataplasme contenant du kétoprofène
EP3238725A4 (fr) Cataplasme
EP3141647A4 (fr) Nappe ouatée
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
EP3259254A4 (fr) Composés thérapeutiques
EP3193878A4 (fr) Composés et méthodes
EP3171876A4 (fr) Polythérapie
EP3204042A4 (fr) Thérapies liées au psma
EP3190116A4 (fr) Composé pyrazolothiazole et médicament
EP3160492A4 (fr) Agent thérapeutique helicobacter
EP3119199A4 (fr) Composés et procédés d&#39;utilisation desdits composés
EP3197470A4 (fr) Cis-gnetin h et trans-gnetin h en tant qu&#39;agents thérapeutiques
EP3225240A4 (fr) Médicament

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20160913

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170926

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/30 20060101ALI20170920BHEP

Ipc: A61K 31/55 20060101AFI20170920BHEP

Ipc: A61P 25/04 20060101ALI20170920BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190408

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS